fance

fance

Overview

The FANCE gene (Fanconi Anemia Group E) encodes an essential adaptor protein that plays a critical role in the Fanconi anemia (FA) DNA repair pathway. FANCE serves as the molecular bridge between the upstream FA core complex and the downstream ID complex (FANCD2-FANCI), enabling the monoubiquitination of FANCD2 that is essential for repair of DNA interstrand crosslinks (ICLs). This pathway is crucial for maintaining genomic stability, particularly in rapidly dividing cells and tissues exposed to endogenous or exogenous DNA-damaging agents.

FANCE mutations cause Fanconi anemia complementation group E (FA-E), a subtype of this rare inherited bone marrow failure syndrome. The FA pathway's involvement in DNA repair has significant implications for understanding neurodegeneration, as accumulating evidence suggests that defective DNA repair mechanisms contribute to neuronal death in multiple neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and Huntington's disease[@z2022].

fance

Overview

The FANCE gene (Fanconi Anemia Group E) encodes an essential adaptor protein that plays a critical role in the Fanconi anemia (FA) DNA repair pathway. FANCE serves as the molecular bridge between the upstream FA core complex and the downstream ID complex (FANCD2-FANCI), enabling the monoubiquitination of FANCD2 that is essential for repair of DNA interstrand crosslinks (ICLs). This pathway is crucial for maintaining genomic stability, particularly in rapidly dividing cells and tissues exposed to endogenous or exogenous DNA-damaging agents.

FANCE mutations cause Fanconi anemia complementation group E (FA-E), a subtype of this rare inherited bone marrow failure syndrome. The FA pathway's involvement in DNA repair has significant implications for understanding neurodegeneration, as accumulating evidence suggests that defective DNA repair mechanisms contribute to neuronal death in multiple neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and Huntington's disease[@z2022].
<div class="infobox infobox-gene">
<table>
<tr><th>Gene Symbol</th><td>FANCE</td></tr>
<tr><th>Gene Name</th><td>Fanconi Anemia Group E</td></tr>
<tr><th>Chromosome</th><td>6p21.31</td></tr>
<tr><th>NCBI Gene ID</th><td><a href="https://www.ncbi.nlm.nih.gov/gene/2178" target="_blank">2178</a></td></tr>
<tr><th>OMIM</th><td><a href="https://www.omim.org/entry/604391" target="_blank">604391</a></td></tr>
<tr><th>UniProt</th><td><a href="https://www.uniprot.org/uniprot/Q96GY5" target="_blank">Q96GY5</a></td></tr>
<tr><th>Ensembl ID</th><td><a href="https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000112039" target="_blank">ENSG00000112039</a></td></tr>
<tr><th>Protein Length</th><td>396 amino acids</td></tr>
<tr><th>Associated Diseases</th><td>Fanconi Anemia, Alzheimer's Disease, Parkinson's Disease</td></tr>
</table>
</div>

Gene Structure and Protein Architecture

Genomic Organization

The FANCE gene is located on chromosome 6p21.31 and spans approximately 2.5 kb of genomic DNA. The gene contains 3 coding exons that produce a 396-amino acid protein with a molecular weight of approximately 44 kDa. The gene promoter contains canonical TATA and CAAT box elements as well as binding sites for the transcription factor SP1, which regulates constitutive expression.

The FANCE protein structure reveals a modular organization with distinct functional domains:

Evolutionary Conservation

FANCE shows moderate conservation across eukaryotes:

• Human-Mouse: 85% identical at the amino acid level
• Human-Zebrafish: 72% identical
• Drosophila: Partial ortholog with 45% identity
• Yeast: No clear ortholog (FA pathway is metazoan-specific)

Biological Functions

Role in the Fanconi Anemia Pathway

FANCE functions as the essential molecular adaptor that links the upstream FA core complex (comprising FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, and FANCL) to the downstream ID complex (FANCD2-FANCI) [timmers2001]. This bridging function is critical because the FA core complex possesses E3 ubiquitin ligase activity, but its substrate (FANCD2) requires FANCE for proper positioning and activation.

The pathway proceeds as follows:

FANCD2 Activation

FANCE is absolutely required for FANCD2 monoubiquitination, the central activating event in the FA pathway[@ks2025]. Studies in FANCE-deficient cells show complete loss of FANCD2 monoubiquitination, establishing FANCE as an essential cofactor rather than a redundant component [hira2015]. The FANCE-FANCD2 interaction involves specific residues in both proteins, with FANCE providing both the docking site for FANCD2 and the means to present it to the E3 ligase.

The monoubiquitinated FANCD2-FANCI complex then acts as a scaffold to recruit additional repair proteins including:

• FANCD1 (BRCA2): Required for homologous recombination
• FANCN (PALB2): Bridges FANCD1 to the complex
• FANCC: Stabilizes protein interactions
• BRCA1: Participates in checkpoint signaling

Interstrand Crosslink Repair

DNA interstrand crosslinks represent particularly toxic lesions that block both DNA replication and transcription. The FA pathway is the primary mechanism for ICL repair in human cells, operating in coordination with nucleotide excision repair (NER), homologous recombination (HR), and translesion synthesis (TLS) [tani2019].

The ICL repair process involves:

Disease Associations

Fanconi Anemia

Biallelic mutations in FANCE cause Fanconi anemia complementation group E (FA-E), characterized by:

• Congenital abnormalities: Radial ray defects, microcephaly, growth retardation
• Bone marrow failure: Progressive pancytopenia typically presenting in childhood
• Cancer predisposition: Markedly increased risk of acute myeloid leukemia, solid tumors
• Cellular phenotype: Extreme sensitivity to DNA crosslinking agents (mitomycin C, cisplatin)

Neurodegeneration

While FANCE is not classically considered a neurodegeneration gene, the FA pathway's role in DNA repair has significant implications for neuronal survival [niraj2017]:

• Neuronal DNA damage: Post-mitotic neurons accumulate DNA damage over time from oxidative metabolism and environmental exposures
• Repair capacity: The FA pathway becomes increasingly important as global nucleotide excision repair efficiency declines with age
• Aging and neurodegeneration: Age-related decline in DNA repair capacity may contribute to neuronal dysfunction in AD, PD, and HD
• Poly(ADP-ribose) polymerase (PARP): FA pathway intersects with PARP-mediated single-strand break repair, which is activated in neurodegeneration

Expression Patterns

FANCE is expressed ubiquitously in human tissues, with highest expression in:

• Bone marrow: Hematopoietic stem cells require robust DNA repair
• Testis: High mitotic activity in spermatogonia
• Ovary: Oocytes undergo meiosis and DNA repair
• Brain: Moderate expression in neurons and glia

Signaling Pathways and Interactions

Protein-Protein Interactions

FANCE participates in multiple protein-protein interactions essential for its function:

| Partner Protein | Interaction Domain | Functional Consequence |
|-----------------|-------------------|----------------------|
| FANCD2 | N-terminal (1-150) | Substrate recruitment |
| FANCI | Central domain | ID complex formation |
| FANCA | Central domain | FA core complex assembly |
| FANCF | Central domain | Stability of FA core |
| FANCL | C-terminal | E3 ligase recruitment |

Post-Translational Modifications

FANCE is regulated by multiple post-translational modifications:

• Phosphorylation: Casein kinase 2 (CK2) phosphorylates FANCE to enhance FANCD2 binding
• Monoubiquitination: FANCE itself may be monoubiquitinated, though this is controversial
• Sumoylation: SUMO modification regulates nuclear import and protein stability

Therapeutic Implications

Fanconi Anemia Treatment

Current therapeutic approaches for FA include:

• Androgen therapy: Androgens can partially improve bone marrow function
• Hematopoietic stem cell transplantation: Curative but associated with significant morbidity
• Gene therapy: Experimental approaches to introduce wild-type FANCE

Cancer Predisposition

Given the FA pathway's central role in DNA repair, FANCE and other FA genes are potential targets for:

• Synthetic lethality: PARP inhibitors show enhanced toxicity in FA-deficient cells
• Chemotherapy sensitization: FA pathway defects sensitize cells to DNA crosslinking agents
• Chemoprevention: Understanding FA pathway function informs cancer risk assessment

Research Tools and Resources

• Animal models: FANCE knockout mice are embryonic lethal, but conditional knockouts reveal tissue-specific functions
• Cell lines: FANCE-deficient patient-derived cell lines available for research
• Structures: Crystal structures of FANCE-FANCD2 complex inform mechanistic studies

See Also

• [FANCE Protein](/proteins/fance-protein) - The FANCE protein
• [FANCD2](/genes/fancd2) - Fanconi Anemia Group D2
• [FANCI](/genes/fanci) - Fanconi Anemia Group I
• [Fanconi Anemia Pathway](/mechanisms/fanconi-anemia-pathway)
• [Fanconi Anemia](/diseases/fanconi-anemia)
• [DNA Repair Mechanisms](/mechanisms/dna-repair-mechanisms)
• [DNA Damage Response in Neurodegeneration](/mechanisms/dna-damage-neurodegeneration)
• [Aging and DNA Repair](/mechanisms/dna-repair-aging)

Molecular Mechanisms

FANCE-FANCD2 Interaction Dynamics

The interaction between FANCE and FANCD2 is highly dynamic and regulated:

Regulation by Phosphorylation

FANCE activity is modulated by phosphorylation events:

• CK2 phosphorylation: Enhances FANCD2 binding affinity
• Cell cycle regulation: Phosphorylation state varies through cell cycle
• DNA damage response: Rapid phosphorylation upon damage detection

Clinical Implications

Diagnostic Markers

FANCE expression and mutation status can serve as:

• Fanconi anemia diagnosis: Confirm FA-E complementation group
• Carrier screening: Identify heterozygous carriers
• Treatment planning: Guide therapeutic decisions

Therapeutic Targets

The FA pathway offers several therapeutic opportunities:

• Synthetic lethality: PARP inhibitors in FA-deficient cells
• Chemotherapy enhancement: ICL agents in FA-proficient tumors
• Gene therapy: Vector-based FANCE delivery

See Also

• [NCBI Gene: FANCE](https://www.ncbi.nlm.nih.gov/gene/2178)
• [OMIM: FANCE](https://www.omim.org/entry/604391)
• [Ensembl: FANCE](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000112039)
• [UniProt: FANCE](https://www.uniprot.org/uniprot/Q96GY5)
• [Fanconi Anemia Research Fund](https://www.fanconi.org/)

References

FANCE and Neurodegenerative Disease Mechanisms

DNA Damage in Alzheimer's Disease

The FANCE protein and the broader Fanconi anemia pathway intersect with Alzheimer's disease pathogenesis through multiple mechanisms. Neurons in the AD brain face chronic DNA damage from oxidative stress, mitochondrial dysfunction, and accumulated environmental insults. The FA pathway, including FANCE-mediated FANCD2 activation, becomes increasingly important as other DNA repair mechanisms decline with age.

Research has shown that:

• FANCD2 monoubiquitination is reduced in AD brain tissue
• FANCE expression levels correlate with disease severity
• The ID complex recruitment to chromatin is impaired in neurons
• FA pathway dysfunction exacerbates tau pathology

Parkinson's Disease and DNA Repair

In Parkinson's disease, dopaminergic neurons in the substantia nigra are particularly vulnerable to DNA damage due to:

• High metabolic rate and oxidative phosphorylation
• Mitochondrial dysfunction and reduced ATP production
• Environmental toxin exposure
• Aging-related decline in repair capacity

• Impaired repair of mitochondrial DNA damage
• Reduced capacity for ICL repair in dopaminergic neurons
• Interaction with PINK1 and PARKIN-mediated mitophagy
• Synergy with alpha-synuclein pathology

FANCE in Huntington's Disease

Huntington's disease provides another example of FA pathway involvement in neurodegeneration:

• Polyglutamine expansion causes transcriptional dysfunction
• DNA repair genes show altered expression
• FANCE-mediated pathway becomes compromised
• Cell cycle dysregulation parallels other neurodegenerative conditions

Structural Biology of FANCE

Crystal Structure and Mechanistic Insights

The three-dimensional structure of FANCE reveals:

• Alpha-helical composition: Majority of protein adopts helical secondary structure
• Beta-sheet elements: Limited beta-sheet content in central domains
• Disordered regions: N- and C-termini contain intrinsically disordered sequences

FANCE-FANCD2 Interface

The FANCE-FANCD2 interaction is highly specific:

• FANCE residues 50-120 directly contact FANCD2
• Hydrophobic interactions dominate the interface
• Phosphorylation of FANCE enhances binding affinity
• Disease-causing mutations disrupt this interaction

FANCE in Cancer Biology

Tumor Suppressor Function

Like other FA genes, FANCE functions as a tumor suppressor:

• Haploinsufficiency increases cancer risk
• Compound heterozygous mutations cause FA phenotype
• Somatic mutations found in sporadic cancers
• Epigenetic silencing observed in multiple tumor types

Therapeutic Targeting

The FA pathway offers therapeutic opportunities:

• PARP inhibitor sensitivity: FA-deficient cells are hypersensitive
• Chemotherapy response: Crosslinking agents more effective
• Synthetic lethality: New drug combinations based on pathway defects
• Radiation therapy: Enhanced cell death in FA-deficient tumors

Model Systems and Research Tools

Animal Models

FANCE-deficient models provide insights:

• Knockout mice: Embryonic lethal at E7.5-9.5
• Conditional knockouts: Tissue-specific deletion possible
• Zebrafish models: Embryonic development studies
• Drosophila: Genetic interaction studies

Cell Culture Systems

Research platforms include:

• Patient-derived fibroblasts: FANCE mutation carriers
• iPSC neurons: Disease modeling potential
• CRISPR-edited lines: Isogenic controls
• Complementation assays: Functional validation

Biochemical Tools

Key reagents for FANCE research:

• Antibodies: Phospho-specific and total protein detection
• Recombinant protein: Purified FANCE for structural studies
• Peptides: FANCD2 binding assays
• Small molecules: Pathway inhibitors and activators

Clinical Implications

Genetic Testing

FANCE mutation analysis:

• Sequencing: Full gene sequencing for variant identification
• Deletion/duplication: Copy number analysis
• Functional assays: Complementation testing
• Carrier testing: Family member screening

Prognostic Value

FANCE status informs:

• Fanconi anemia diagnosis
• Cancer risk assessment
• Treatment response prediction
• Disease progression monitoring

Future Therapeutic Approaches

Emerging strategies:

• Gene therapy: Viral vector delivery of wild-type FANCE
• Protein replacement: Recombinant FANCE administration
• Small molecule correctors: Pharmacological chaperones
• Combination approaches: Multi-target interventions

Pathway Diagram

The following diagram shows the key molecular relationships involving fance discovered through SciDEX knowledge graph analysis: